{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:24:54Z","timestamp":1790472294155,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s40263-018-0562-0","type":"journal-article","created":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T02:26:19Z","timestamp":1534213579000},"page":"785-796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Cladribine Tablets: A Review in Relapsing MS"],"prefix":"10.1007","volume":"32","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"issue":"2","key":"562_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/1352458517751049","volume":"24","author":"X Montalban","year":"2018","unstructured":"Montalban X, Gold R, Thompson AJ, et al. ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler. 2018;24(2):96\u2013120.","journal-title":"Mult Scler."},{"key":"562_CR2","unstructured":"National Multiple Sclerosis Society. What is MS? 2018. https:\/\/www.nationalmssociety.org\/. Accessed 27 July 2018."},{"key":"562_CR3","unstructured":"National Institute of Neurological Disorders and Stroke. Multiple sclerosis information page. 2018. https:\/\/www.ninds.nih.gov\/. Accessed 27 July 2018."},{"key":"562_CR4","unstructured":"Cleveland Clinic. Mellen Center approaches: highly active multiple sclerosis. https:\/\/my.clevelandclinic.org\/. Accessed 30 July 2018."},{"key":"562_CR5","unstructured":"European Medicines Agency. Mavenclad 10\u00a0mg tablets: EU summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/. Accessed 27 July 2018."},{"issue":"11","key":"562_CR6","doi-asserted-by":"publisher","first-page":"6865","DOI":"10.1073\/pnas.77.11.6865","volume":"77","author":"DA Carson","year":"1980","unstructured":"Carson DA, Wasson DB, Kaye J, et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc Natl Acad Sci USA. 1980;77(11):6865\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"562_CR7","first-page":"117","volume":"4","author":"C Warnke","year":"2010","unstructured":"Warnke C, Wiendl H, Hartung HP, et al. Identification of targets and new developments in the treatment of multiple sclerosis\u2014focus on cladribine. Drug Des Dev Ther. 2010;4:117\u201326.","journal-title":"Drug Des Dev Ther."},{"issue":"1","key":"562_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"TP Leist","year":"2011","unstructured":"Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28\u201335.","journal-title":"Clin Neuropharmacol"},{"issue":"24 Pt 1","key":"562_CR9","first-page":"6923","volume":"49","author":"J Griffig","year":"1989","unstructured":"Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res. 1989;49(24 Pt 1):6923\u20138.","journal-title":"Cancer Res"},{"issue":"2","key":"562_CR10","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1172\/JCI111710","volume":"75","author":"S Seto","year":"1985","unstructured":"Seto S, Carrera CJ, Kubota M, et al. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J Clin Invest. 1985;75(2):377\u201383.","journal-title":"J Clin Invest."},{"issue":"4","key":"562_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1182\/blood.V62.4.737.737","volume":"62","author":"DA Carson","year":"1983","unstructured":"Carson DA, Wasson DB, Taetle R, et al. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood. 1983;62(4):737\u201343.","journal-title":"Blood"},{"issue":"1","key":"562_CR12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood.V81.1.143.143","volume":"81","author":"LE Robertson","year":"1993","unstructured":"Robertson LE, Chubb S, Meyn RE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2\u2019-deoxyadenosine and 9-beta-d-arabinosyl-2-fluoroadenine. Blood. 1993;81(1):143\u201350.","journal-title":"Blood"},{"issue":"1","key":"562_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s002800050788","volume":"42","author":"HJ Guchelaar","year":"1998","unstructured":"Guchelaar HJ, Vermes I, Koopmans RP, et al. Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol. 1998;42(1):77\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"Pt 3","key":"562_CR14","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1042\/bj3590537","volume":"359","author":"I Marzo","year":"2001","unstructured":"Marzo I, Perez-Galan P, Giraldo P, et al. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem J. 2001;359(Pt 3):537\u201346.","journal-title":"Biochem J"},{"issue":"5","key":"562_CR15","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa0902533","volume":"362","author":"G Giovannoni","year":"2010","unstructured":"Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416\u201326.","journal-title":"N Engl J Med"},{"issue":"4","key":"562_CR16","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1212\/NXI.0000000000000360","volume":"4","author":"D Baker","year":"2017","unstructured":"Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e360.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"562_CR17","doi-asserted-by":"crossref","unstructured":"Soelberg-Sorensen P, Dangond F, Hicking C, et al. Long-term lymphocyte counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5\u00a0mg\/kg: total lymphocytes, B and T cell subsets [abstract no. P655]. Mult Scler J. 2017;23(S3):310.","DOI":"10.26226\/morressier.59a3eda8d462b8028d8950f6"},{"issue":"2","key":"562_CR18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/cei.12109","volume":"173","author":"V Singh","year":"2013","unstructured":"Singh V, Prajeeth CK, Gudi V, et al. 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. Clin Exp Immunol. 2013;173(2):288\u201397.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"562_CR19","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s11481-012-9387-7","volume":"7","author":"V Singh","year":"2012","unstructured":"Singh V, Voss EV, Benardais K, et al. Effects of 2-chlorodeoxyadenosine (cladribine) on primary rat microglia. J Neuroimmune Pharmacol. 2012;7(4):939\u201350.","journal-title":"J Neuroimmune Pharmacol."},{"issue":"1\u20132","key":"562_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2013.08.009","volume":"264","author":"A Musella","year":"2013","unstructured":"Musella A, Mandolesi G, Gentile A, et al. Cladribine interferes with IL-1beta synaptic effects in experimental multiple sclerosis. J Neuroimmunol. 2013;264(1\u20132):8\u201313.","journal-title":"J Neuroimmunol"},{"key":"562_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jneuroim.2011.09.010","volume":"240\u2013241","author":"B Laugel","year":"2011","unstructured":"Laugel B, Borlat F, Galibert L, et al. Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity. J Neuroimmunol. 2011;240\u2013241:52\u20137.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"562_CR22","doi-asserted-by":"publisher","first-page":"e0129182","DOI":"10.1371\/journal.pone.0129182","volume":"10","author":"M Korsen","year":"2015","unstructured":"Korsen M, Bragado Alonso S, Peix L, et al. Cladribine exposure results in a sustained modulation of the cytokine response in human peripheral blood mononuclear cells. PLoS One. 2015;10(6):e0129182.","journal-title":"PLoS One"},{"issue":"2","key":"562_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.intimp.2013.11.027","volume":"18","author":"SH Kraus","year":"2014","unstructured":"Kraus SH, Luessi F, Trinschek B, et al. Cladribine exerts an immunomodulatory effect on human and murine dendritic cells. Int Immunopharmacol. 2014;18(2):347\u201357.","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"562_CR24","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1468-1331.2008.02433.x","volume":"16","author":"T Kopadze","year":"2009","unstructured":"Kopadze T, Dobert M, Leussink VI, et al. Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol. 2009;16(3):409\u201312.","journal-title":"Eur J Neurol"},{"issue":"6","key":"562_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1600-0404.2010.01330.x","volume":"122","author":"K Mitosek-Szewczyk","year":"2010","unstructured":"Mitosek-Szewczyk K, Stelmasiak Z, Bartosik-Psujek H, et al. Impact of cladribine on soluble adhesion molecules in multiple sclerosis. Acta Neurol Scand. 2010;122(6):409\u201313.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"562_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1517\/17425250903393745","volume":"6","author":"P Hentosh","year":"2010","unstructured":"Hentosh P, Peffley DM. The cladribine conundrum: deciphering the drug\u2019s mechanism of action. Expert Opin Drug Metab Toxicol. 2010;6(1):75\u201381.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"562_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0695-9","author":"R Hermann","year":"2018","unstructured":"Hermann R, Karlsson MO, Novakovic AM, et al. The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis. Clin Pharmacokinet. 2018. https:\/\/doi.org\/10.1007\/s40262-018-0695-9.","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"562_CR28","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s40262-017-0516-6","volume":"56","author":"RM Savic","year":"2017","unstructured":"Savic RM, Novakovic AM, Ekblom M, et al. Population pharmacokinetics of cladribine in patients with multiple sclerosis. Clin Pharmacokinet. 2017;56(10):1245\u201353.","journal-title":"Clin Pharmacokinet"},{"key":"562_CR29","unstructured":"European Medicines Agency. Assessment report: Mavenclad. 2017. http:\/\/www.ema.europa.eu. Accessed 27 July 2018."},{"key":"562_CR30","doi-asserted-by":"crossref","unstructured":"Giovannoni G, Soelberg SP, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2017:1352458517727603.","DOI":"10.1177\/1352458517727603"},{"issue":"Suppl 1","key":"562_CR31","first-page":"21","volume":"19","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Comi G, Cook S, et al. Durable efficacy of cladribine tablets in patients with multiple sclerosis: analysis of relapse rates and relapse-free patients in the CLARITY and CLARITY extension studies [abstract no. DX30 plus poster]. Int J MS Care. 2017;19(Suppl 1):21\u20132.","journal-title":"Int J MS Care."},{"key":"562_CR32","doi-asserted-by":"crossref","unstructured":"Montalban X, Cohen B, Leist T, et al. Efficacy of cladribine tablets 3.5\u00a0mg\/kg added to interferon-beta in patients with SPMS or relapsing- RRMS: a post hoc analysis from ONWARD [abstract no. 0766]. In: 4th Congress of the European Academy of Neurology. 2018.","DOI":"10.1212\/NXI.0000000000000477"},{"key":"562_CR33","unstructured":"Giovannoni G, Montalban X, Hicking C, et al. Pooled analysis of the efficacy of cladribine tablets 3.5\u00a0mg\/kg in patients with EDSS\u2009\u2265\u20093.5 or\u2009\u2264\u20093.0 at baseline in the CLARITY and ONWARD studies [abstract no. 0747]. In: 4th Congress of the European Academy of Neurology. 2018."},{"issue":"4","key":"562_CR34","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s00415-012-6775-0","volume":"260","author":"G Comi","year":"2013","unstructured":"Comi G, Cook SD, Giovannoni G, et al. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol. 2013;260(4):1136\u201346.","journal-title":"J Neurol"},{"issue":"2","key":"562_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ana.20883","volume":"60","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Lee JC, Simon J, et al. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol. 2006;60(2):236\u201342.","journal-title":"Ann Neurol"},{"key":"562_CR36","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517690269","author":"N De Stefano","year":"2017","unstructured":"De Stefano N, Giorgio A, Battaglini M, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler. 2017. https:\/\/doi.org\/10.1177\/1352458517690269.","journal-title":"Mult Scler."},{"key":"562_CR37","doi-asserted-by":"publisher","first-page":"175628561775336","DOI":"10.1177\/1756285617753365","volume":"11","author":"G Comi","year":"2018","unstructured":"Comi G, Cook S, Rammohan K, et al. Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY extension study. Ther Adv Neurol Disord. 2018;11:1756285617753365.","journal-title":"Ther Adv Neurol Disord."},{"issue":"4","key":"562_CR38","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(11)70023-0","volume":"10","author":"G Giovannoni","year":"2011","unstructured":"Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329\u201337.","journal-title":"Lancet Neurol."},{"key":"562_CR39","doi-asserted-by":"crossref","unstructured":"Afolabi D, Albor C, Zalewski L, et al. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis. Mult Scler. 2017:1352458517726380.","DOI":"10.1177\/1352458517726380"},{"key":"562_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518771875","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Soelberg Sorensen P, Cook S, et al. Efficacy of cladribine tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: a post hoc analysis of the CLARITY study. Mult Scler. 2018. https:\/\/doi.org\/10.1177\/1352458518771875.","journal-title":"Mult Scler."},{"issue":"1","key":"562_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.msard.2011.08.006","volume":"1","author":"K Rammohan","year":"2012","unstructured":"Rammohan K, Giovannoni G, Comi G, et al. Cladribine tablets for relapsing\u2013remitting multiple sclerosis: efficacy across patient subgroups from the phase III CLARITY study. Mult Scler Relat Disord. 2012;1(1):49\u201354.","journal-title":"Mult Scler Relat Disord."},{"issue":"5","key":"562_CR42","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1177\/1352458510391344","volume":"17","author":"S Cook","year":"2011","unstructured":"Cook S, Vermersch P, Comi G, et al. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult Scler J. 2011;17(5):578\u201393.","journal-title":"Mult Scler J."},{"issue":"Suppl 1","key":"562_CR43","first-page":"37","volume":"19","author":"S Cook","year":"2017","unstructured":"Cook S, Leist T, Comi G, et al. Cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis of safety from the multiple sclerosis clinical development program [abstract no. DX69]. Int J MS Care. 2017;19(Suppl 1):37.","journal-title":"Int J MS Care."},{"key":"562_CR44","doi-asserted-by":"crossref","unstructured":"Galazka A, Nolting A, Cook S, et al. An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis (RMS) [abstract no. P1878]. Mult Scler J. 2017;23(S3):999\u20131000.","DOI":"10.26226\/morressier.59a96e1dd462b8028d895a81"},{"issue":"6","key":"562_CR45","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1212\/NXI.0000000000000158","volume":"2","author":"J Pakpoor","year":"2015","unstructured":"Pakpoor J, Disanto G, Altmann DR, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm. 2015;2(6):e158.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"issue":"12","key":"562_CR46","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00415-017-8594-9","volume":"264","author":"G Pardo","year":"2017","unstructured":"Pardo G, Jones DE. The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017;264(12):2351\u201374.","journal-title":"J Neurol"},{"issue":"1","key":"562_CR47","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3988\/jcn.2015.11.1.9","volume":"11","author":"W Kim","year":"2015","unstructured":"Kim W, Zandona M, Kim S, et al. Oral disease-modifying therapies for multiple sclerosis. J Clin Neurol. 2015;11(1):9\u201319.","journal-title":"J Clin Neurol."},{"issue":"5","key":"562_CR48","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","volume":"65","author":"DL Vargas","year":"2017","unstructured":"Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Invest Med. 2017;65(5):883\u201391.","journal-title":"J Invest Med."},{"key":"562_CR49","unstructured":"De Stefano N, Achiron A, Barkhof F, et al. The MAGNIFY-MS study: mavenclad tablets in active RMS [poster no. 174]. In: Annual Meeting of the Association of British Neurologists. 2018."},{"key":"562_CR50","unstructured":"Schippling S, Langdon D, Solari A, et al. Phase IV study of cladribine tablets and quality of life: CLARIFY-MS [poster no. 172]. In: Annual Meeting of the Association of British Neurologists. 2018."},{"key":"562_CR51","unstructured":"Merck. FDA accepts file for cladribine tablets as potential treatment for relapsing forms of multiple sclerosis [media release]. 30 July 2018. https:\/\/www.merckgroup.com."},{"issue":"5","key":"562_CR52","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11910-012-0295-2","volume":"12","author":"V Yadav","year":"2012","unstructured":"Yadav V, Bourdette D. New disease-modifying therapies and new challenges for MS. Curr Neurol Neurosci Rep. 2012;12(5):489\u201391.","journal-title":"Curr Neurol Neurosci Rep."},{"key":"562_CR53","unstructured":"National Institute for Health and Care Excellence. Cladribine tablets for treating relapsing-remitting multiple sclerosis: technology appraisal guidance. 2017. http:\/\/www.nice.org.uk. Accessed 27 July 2018."},{"issue":"4","key":"562_CR54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/practneurol-2015-001139","volume":"15","author":"N Scolding","year":"2015","unstructured":"Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15(4):273\u20139.","journal-title":"Pract Neurol."},{"key":"562_CR55","doi-asserted-by":"crossref","unstructured":"Kalincik T, Jokubaitis V, Spelman T, et al. Cladribine versus fingolimod, natalizumab and interferon \u03b2 for multiple sclerosis. Mult Scler. 2017:1352458517728812.","DOI":"10.1177\/1352458517728812"},{"issue":"8","key":"562_CR56","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/03007995.2017.1407303","volume":"34","author":"MK Siddiqui","year":"2018","unstructured":"Siddiqui MK, Khurana IS, Budhia S, et al. Systematic literature review and network meta-analysis of cladribine tablets versus alternative disease-modifying treatments for relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2018;34(8):1361\u201371.","journal-title":"Curr Med Res Opin"},{"key":"562_CR57","doi-asserted-by":"crossref","unstructured":"Mitsikostas DD, Deligianni C. Absolute and relative change in NEDA after treatment with oral disease modifying treatments in MS patients [abstract]. Neurology. 2017;88(16 Suppl. 1).","DOI":"10.1212\/WNL.88.16_supplement.P4.387"},{"key":"562_CR58","doi-asserted-by":"crossref","unstructured":"Mitsikostas DD, Papadopoulos D. Comparing benefit-risk profiles of oral DMTs for relapsing MS: a likelihood of help vs. harm (LHH) analysis [abstract no. P4.388]. Neurology. 2018;90(15 Suppl).","DOI":"10.1212\/WNL.90.15_supplement.P4.388"},{"key":"562_CR59","unstructured":"Vermersch P, Martinelli V, Pfleger C, et al. Benefit-risk assessment of cladribine tablets using multi-criteria decision analysis (MCDA) for patients with relapsing multiple sclerosis demonstrating high disease activity [abstract no. 0759 plus poster]. In: 4th Congress of the European Academy of Neurology. 2018."},{"key":"562_CR60","unstructured":"Harty G, Damian D, Budhia S, et al. Subsequent disease modifying drug treatment of patients treated with cladribine tablets [poster no. 191]. In: Annual Meeting of the Association of British Neurologists. 2018."},{"issue":"8","key":"562_CR61","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1136\/jnnp.2006.090365","volume":"77","author":"G Kobelt","year":"2006","unstructured":"Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918\u201326.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"562_CR62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2165\/11593310-000000000-00000","volume":"32","author":"S Ali","year":"2012","unstructured":"Ali S, Paracha N, Cook S, et al. Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. Clin Drug Investig. 2012;32(1):15\u201327.","journal-title":"Clin Drug Investig."},{"issue":"7","key":"562_CR63","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/13696998.2018.1461630","volume":"21","author":"R Hettle","year":"2018","unstructured":"Hettle R, Harty G, Wong SL. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. J Med Econ. 2018;21(7):676\u201386.","journal-title":"J Med Econ."}],"updated-by":[{"DOI":"10.1007\/s40263-019-00604-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-018-0562-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0562-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0562-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T06:01:18Z","timestamp":1720504878000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-018-0562-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0562-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-019-00604-8","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"14 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The article Cladribine Tablets: A Review in Relapsing MS, written by Emma D. Deeks, was originally published Online First without open access.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emma Deeks is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}